Farren and colleagues have shown that the CD160 is overexpressed in malignant B cells, but not in healthy B cells, indicating CD160 as a tumor-specific marker of malignant B lymphocytes (Farren et al., 2011). This evidence concerns the gene CD160 and neoplasm.